{"schema_version":"secwatch.filing_event.v1","accession":"0001000694-23-000050","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.809678+00:00","generated_at":"2026-06-12T00:09:58.150298+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Novavax Q2 net income $58M on $424M revenue; SK bio partnership & Canada APA strengthen finances","bullets":["Q2 total revenue $424M (up from $186M); net income $58M vs net loss $510M in Q2 2022.","Updated FY 2023 revenue guidance to $1.3B-1.5B (from $1.4B-1.6B); combined R&D/SG&A cut to $313M from $398M.","SK bioscience $85M equity investment at $13/share (59% premium); $195M manufacturing liability settled for $154M.","Initiated FDA submission for updated XBB COVID vaccine; expect availability by September 2023.","Reduced current liabilities by $864M in H1 2023; total reduction over $1B including SK bioscience deal."],"urls":{"canonical":"https://secwatch.observer/filing/0001000694-23-000050","json":"https://secwatch.observer/filing/0001000694-23-000050.json","markdown":"https://secwatch.observer/filing/0001000694-23-000050.md","text":"https://secwatch.observer/filing/0001000694-23-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000050/0001000694-23-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000050/nvax-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T00:09:58.150298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6deceee62f8f807a6fcf663e161b253d05eb3fae","claim":"NOVAVAX INC reported Quarter Ended June 30, 2023 results: revenue $424 million, net income $58 million.","evidence_excerpt":"Novavax Reports Second Quarter 2023 Financial Results and Operational Highlights • Second quarter total revenue of $424 million and net income of $58 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000050/0001000694-23-000050-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Quarter Ended June 30, 2023"},{"label":"Revenue","value":"$424 million"},{"label":"Net income","value":"$58 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}